Compare Eli Lilly And Co (LLY) vs Nutrien Ltd (NTR) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Nutrien (NTR) trades at $66.40, down 1.31% on the day, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.51 versus $0.48, and revenue trending upward to $26.89B in 2025. Valuation ratios appear attractive with a P/E of 13.7 and P/S of 1.17. Analyst sentiment is positive with a consensus price target of $77.67, representing 17% upside, and 61% of analysts rate it a Buy.

The outlook for Nutrien is favorable due to strong fertilizer demand and cost management, though risks include volatile input costs and competitive pressures. With solid cash flow from operations and a dividend payout, the stock offers value and income potential, but investors should monitor global agricultural trends and energy market impacts on margins.